Halozyme Therapeutics, Inc. logo

HALO

Halozyme Therapeutics, Inc.

$54.67

Earnings Summary

Revenue
$39.15Mn
Net Profits
$-14.62Mn
Net Profit Margins
-37.36%

Highlights

Revenue:

Halozyme Therapeutics, Inc.’s revenue jumped 11.21% since last year same period to $39.15Mn in the Q2 2019. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -31.26% fall in its revenue since last 3-months.

Net Profits:

Halozyme Therapeutics, Inc.’s net profit jumped 36.12% since last year same period to $-14.62Mn in the Q2 2019. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -914.25% fall in its net profits since last 3-months.

Net Profit Margins:

Halozyme Therapeutics, Inc.’s net profit margin jumped 42.56% since last year same period to -37.36% in the Q2 2019. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -1284.5% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Halozyme Therapeutics, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
0.4
EPS Estimate Current Year
0.4

Highlights

EPS Estimate Current Quarter:

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.4 - a 24.74% jump from last quarter’s estimates.

EPS Estimate Current Year:

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.4.

Key Ratios

Key ratios of the Halozyme Therapeutics, Inc. post its Q2 2022 earnings

Earning Per Share (EPS)
0.16
Return on Assets (ROA)
0.11
Return on Equity (ROE)
1.12

Highlights

Earning Per Share (EPS):

Halozyme Therapeutics, Inc.’s earning per share (EPS) fell -74.19% since last year same period to 0.16 in the Q2 2022. This indicates that the Halozyme Therapeutics, Inc. has generated -74.19% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Halozyme Therapeutics, Inc.’s return on assets (ROA) stands at 0.11.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Halozyme Therapeutics, Inc.’s return on equity (ROE) stands at 1.12.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
0.46
0.43
-6.79%
2022-08-09
0.47
0.16
-65.96%

Company Information

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.

Organisation
Halozyme Therapeutics, Inc.
Headquarters
11388 Sorrento Valley Road, San Diego, CA, United States, 92121
Employees
145
Industry
Health Technology
CEO
Helen Torley

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*